Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) cost per dose and what the patient owes

$48.06 per mg is Part B's ASP+6% rate for Q3 2026. Once the $283 Part B deductible is met, the patient owes the remaining 20% coinsurance on the drug and its administration, with no annual out-of-pocket maximum to cap it. On this drug that coinsurance is larger than on any other claim on this site: $44,215.20 of drug on a single line, well above Keytruda's $12,129 allowed amount, the previous high. Full explanation: How Medicare Part B drug cost sharing works →

Medicare pays J2351 per 1 mg billing unit, not per vial or per dose. Ocrevus Zunovo's labeled dose is a flat 920 mg for every indication, drawn whole from one 920 mg single-dose vial — so the allowed drug amount is the same $44,215.20 every time, and JZ belongs on every claim because there is no drug left over to discard.

Ocrevus Zunovo's per-milligram rate is lower than infused Ocrevus. Its labeled dose is larger. The second fact outweighs the first.

J2351 is $12.91 per mg cheaper than J2350 and still costs $15,266.40 more a year, because the labeled dose is 920 mg against 600 mg. That inverts the assumption most people bring to a subcutaneous switch. Briumvi is a different molecule (ublituximab-xiiy, TG Therapeutics) shown here for scale, not as a clinical recommendation — CareCost does not compare drugs on clinical grounds. The IV product's own first year carries a third claim (a split 300 mg loading dose 14 days after the first), which this table does not add in; Zunovo has no loading split at all.

Genentech's own billing guidance leads with 96401 (subcutaneous non-hormonal anti-neoplastic, $71.81), and this page's estimator defaults to it. Some payers require 96372 (therapeutic subcutaneous injection, $15.36) instead — a 4.7x spread on the same ten-minute injection, decided by payer policy rather than by what happens in the chair.

On the reference claim, that changes the total allowed amount from $44,287.01 (with 96401) to $44,230.56 (with 96372) — a $56.45 difference. It barely moves the patient's 20% coinsurance: $8,857.40 against $8,846.11, an $11.29 difference. The drug dominates the claim so completely that the code fight matters to the practice's reimbursement, not to the patient's bill. Confirm the payer's position before the first claim.

For the reference dose — 920 mg, 920 units, drug + the 96401 administration code — Medicare allows $44,287.01, and the Part B coinsurance on that is $8,857.40. Plans A, B, C, D, F, G, M and N cover that coinsurance in full, so those patients owe nothing per dose once the $283 deductible is met. Plans K and L do not — and because the claim itself is this large, the plan's annual out-of-pocket maximum becomes the story instead of the deductible. A Plan K patient owes $4,683.40 at the dose that lands before the deductible is met, and $4,428.70 at the dose after it. Two doses a year cross Plan K's $8,000 annual out-of-pocket maximum on the second dose — every year, for as long as the patient stays on this drug. See what each Medigap plan (A–N) owes on this claim →

Only the letters that leave this patient a balance are listed. The full A–N grid, the high-deductible variants, Plan N's office-visit carve-out and the MACRA restriction on Plans C and F are at Medigap Plans A–N. Compare this with the site's other clusters: on Venofer the whole claim is smaller than the Part B deductible. Same plan letters, opposite conclusion.

Commercial payers negotiate their own rate for J2351, not ASP+6% — our corpus holds published rates from 36 payers, including Aetna, UnitedHealthcare, Cigna, Anthem, Regence, Premera and Kaiser. Aetna's median is $48.36 per mg against Medicare's $48.06, putting a 920 mg dose at $44,491.20 before benefits. Rates move by state as well as by payer, which is why the estimator above takes one. What the patient owes then depends on their specific benefits. Full explanation: How commercial drug reimbursement works →

Ocrevus Zunovo is a short in-office subcutaneous injection into the abdomen, not an infusion, so claims bill under the physician fee schedule's injection or chemo-administration code (96401 or 96372) rather than a hospital-outpatient facility fee. The coverage corpus for ocrelizumab — shared by Ocrevus Zunovo and the IV formulation — carries 251 rules across 27 payers; 11 of those address site of care, most requiring an in-office or specific outpatient setting rather than allowing any site. See the full coverage requirements for this drug →

There is no 2025 Q1 entry — Ocrevus Zunovo had no published ASP rate that quarter; J2351 became a permanent J-code on April 1, 2025. The Q2 2026 rate ($46.794) applied to a 920 mg dose is $43,050.48 — a figure that still shows up on this site's own retired flat billing page. The current Q3 2026 rate applied to the same 920 mg dose is $44,215.20. Use the quarter that is actually in effect for the claim's date of service.

Genentech runs two open programs for Ocrevus Zunovo: the Ocrevus Co-pay Program, which covers up to $20,000 a year toward the drug and up to $1,500 toward administration in the first year ($1,000 each year after), and the Genentech Patient Foundation, free drug for qualifying uninsured patients. Neither program can be used by a patient on Medicare, Medicaid, TRICARE, VA or another government program. On the reference claim, the $20,000 drug cap covers less than half of a single dose's $44,215.20 allowed drug amount — it narrows the bill, it does not clear it. The $1,500 administration cap works the other way: it comfortably covers the $71.81 96401 line, so for a commercially insured patient on this program the contested administration-code question is a billing detail for the practice, not a cost to the patient. See both programs, with current status →

Sources: CMS ASP pricing files (Q3 2026); Medicare physician fee schedule (96401/96372, national non-facility); Medicare Part B deductible (2026); Medicare Rights Center 2026 Medigap plan benefits chart; 36 commercial payer published price files (Q2 2026); Genentech Ocrevus Co-pay Program and Genentech Patient Foundation terms and status for Ocrevus Zunovo (data/programs/J2351.json, generated from the live programs corpus).

Reviewed September 13, 2026 by Erin Rose, CareCost Estimate founder. Methodology →